OTC Monograph Drug User Fee Transparency Act

Hozzl · 2025-08-07T05:23:21Z

Explore the details of Senate Bill 2513 OTC Monograph Drug User Fee Transparency Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

8/7/2025, 5:23 AM

Summary of Bill S 2513

The bill, designated as S. 2513 in the 119th Congress and introduced on July 29, 2025, aims to amend the Federal Food, Drug, and Cosmetic Act to enhance transparency and reporting concerning over-the-counter drug monograph activities, among other purposes.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 2513

Bill S 2513 is currently in the status of Bill Introduced since July 29, 2025. Bill S 2513 was introduced during Congress 119 and was introduced to the Senate on July 29, 2025. Bill S 2513's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of July 29, 2025

Bipartisan Support of Bill S 2513

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 2513

Primary Policy Focus

Alternate Title(s) of Bill S 2513

OTC Monograph Drug User Fee Transparency Act

A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to transparency and reporting regarding over-the-counter drug monograph activities, and for other purposes.